Intravenous glial-derived neurotrophic factor gene therapy of experimental Parkinson's disease with Trojan horse liposomes and a tyrosine hydroxylase promoter

Journal of Gene Medicine

Volumn 10, Issue 3, 2008, Pages 306-315

  Xia, Chun Fang ^a   Boado, Ruben J ^a   Zhang, Yun ^a   Chu, Chun ^a   Pardridge, William M ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Blood brain barrier; Brain gene therapy; Non viral gene transfer; Tyrosine hydroxylase

Indexed keywords

APOMORPHINE; COMPLEMENTARY DNA; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; GROWTH HORMONE; LIPOSOME; OXIDOPAMINE; PLASMID DNA; TROJAN HORSE LIPOSOME; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG;

ADRENAL GLAND; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOMEGALOVIRUS; DNA FLANKING REGION; DOSE TIME EFFECT RELATION; ENZYME ACTIVITY; GENE EXPRESSION; GENE SEQUENCE; HUMAN; HUMAN CELL; MALE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PLASMID; PRIORITY JOURNAL; PROMOTER REGION; RAT; SEQUENCE ANALYSIS; SUBSTANTIA NIGRA; TRANSCRIPTION TERMINATION;

BOVINAE; CYTOMEGALOVIRUS; EQUIDAE; EUKARYOTA; RATTUS;

EID: 40549111959     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1152     Document Type: Article

References (34)

1. 1 Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F. GDNF: a glial cell line‐derived neurotrophic factor for midbrain dopaminergic neurons. Science 1993 ; 260: 1130–1132.
2. 2 Hoffer BJ, Hoffman A, Bowenkamp K, et al. Glial cell line‐derived neurotrophic factor reverses toxin‐induced injury to midbrain dopaminergic neurons in vivo. Neurosci Lett 1994 ; 182: 107–111.
3. 3 Lapchak PA, Miller PJ, Collins F, Jiao S. Glial cell line‐derived neurotrophic factor attenuates behavioural deficits and regulates nigrostriatal dopaminergic and peptidergic markers in 6‐hydroxydopamine‐lesioned adult rats: comparison of intraventricular and intranigral delivery. Neuroscience 1997 ; 78: 61–72.
4. 4 Kastin AJ, Akerstrom V, Pan W. Glial cell line‐derived neurotrophic factor does not enter normal mouse brain. Neurosci Lett 2003 ; 340: 239–241.
5. 5 Patel NK, Bunnage M, Plaha P, et al. Intraputamenal infusion of glial cell line‐derived neurotrophic factor in PD: a two‐year outcome study. Ann Neurol 2005 ; 57: 298–302.
6. 6 Kordower JH, Emborg ME, Bloch J, et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000 ; 290: 767–773.
7. 7 Georgievska B, Kirik D, Bjorklund A. Aberrant sprouting and downregulation of tyrosine hydroxylase in lesioned nigrostriatal dopamine neurons induced by long‐lasting overexpression of glial cell line derived neurotrophic factor in the striatum by lentiviral gene transfer. Exp Neurol 2002 ; 177: 461–474.
8. 8 Eslamboli A, Georgievska B, Ridley RM, et al. Continuous low‐level glial cell line‐derived neurotrophic factor delivery using recombinant adeno‐associated viral vectors provides neuroprotection and induces behavioral recovery in a primate model of Parkinson's disease. J Neurosci 2005 ; 25: 769–777.
9. 9 Brizard M, Carcenac C, Bemelmans AP, et al. Functional reinnervation from remaining DA terminals induced by GDNF lentivirus in a rat model of early Parkinson's disease. Neurobiol Dis 2006 ; 21: 90–101.
10. 10 Do Thi NA, Saillour P, Ferrero L, Paunio T, Mallet J. Does neuronal expression of GDNF effectively protect dopaminergic neurons in a rat model of Parkinson's disease? Gene Ther 2007 ; 14: 441–450.
11. 11 Pardridge WM. Gene targeting in vivo with pegylated immunoliposomes. Methods Enzymol 2003 ; 373: 507–528.
12. 12 Shi N, Boado RJ, Pardridge WM. Receptor‐mediated gene targeting to tissues in the rat in vivo. Pharm Res 2001 ; 18: 1091–1095.
13. 13 Shi N, Zhang Y, Boado RJ, Zhu C, Pardridge WM. Brain‐specific expression of an exogenous gene after iv. administration. Proc Natl Acad Sci USA 2001 ; 98: 12754–12759.
14. 14 Zhang Y, Schlachetzki F, Pardridge WM. Global non‐viral gene transfer to the primate brain following intravenous administration. Mol Ther 2003 ; 7: 11–18.
15. 15 Zhang Y, Schlachetzki F, Li JY, Boado RJ, Pardridge WM. Organ‐specific gene expression in the rhesus monkey eye following intravenous non‐viral gene transfer. Mol Vis 2003 ; 9: 465–472.
16. 16 Zhu C, Zhang Y, Zhang YF, et al. Organ‐specific expression of the lacZ gene controlled by the opsin promoter after intravenous gene administration in adult mice. J Gene Med 2004 ; 6: 906–912.
17. 17 Chun HS, Yoo MS, DeGiorgio LA, et al. Marked dopaminergic cell loss subsequent to developmental, intranigral expression of glial cell line‐derived neurotrophic factor. Exp Neurol 2002 ; 173: 235–244.
18. 18 Xia CF, Chu C, Li JY, et al. Comparison of cDNA and genomic forms of tyrosine hydroxylase gene therapy of the brain with Trojan horse liposomes. J Gene Med 2007 ; 9: 605–612.
19. 19 Pardridge WM. Non‐viral gene transfer across the blood‐brain barrier with Trojan horse liposomes. In Gene Transfer: Delivery and Expression of DNA and RNA, Friedmann T, Rossi J (eds). Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 2007 ; 701–710.
20. 20 Zhang Y, Calon F, Zhu C, Boado RJ, Pardridge WM. Intravenous nonviral gene therapy causes normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism. Hum Gene Ther 2003 ; 14: 1–12.
21. 21 Tanaka M, Xiao H, Hirata Y, Kiuchi K. A rapid assay for glial cell line‐derived neurotrophic factor and neurturin based on transfection of cells with tyrosine hydroxylase promoter‐luciferase construct. Brain Res Protoc 2003 ; 11: 119–122.
22. 22 Zhang Y, Schlachetzki F, Zhang YF, Boado RJ, Pardridge WM. Normalization of striatal tyrosine hydroxylase and reversal of motor impairment in experimental parkinsonism with intravenous nonviral gene therapy and a brain‐specific promoter. Hum Gene Ther 2004 ; 15: 339–350.
23. 23 Kaneda N, Sasaoka T, Kobayashi K, et al. Tissue‐specific and high‐level expression of the human tyrosine hydroxylase gene in transgenic mice. Neuron 1991 ; 6: 583–594.
24. 24 Kessler MA, Yang M, Gollomp KL, Jin H, Iacovitti L. The human tyrosine hydroxylase gene promoter. Brain Res Mol Brain Res 2003 ; 112: 8–23.
25. 25 Min N, Joh TH, Kim KS, Peng C, Son JH. 5′ Upstream DNA sequence of the rat tyrosine hydroxylase gene directs high‐level and tissue‐specific expression to catecholaminergic neurons in the central nervous system of transgenic mice. Mol Brain Res 1994 ; 27: 281–289.
26. 26 Kim TE, Park MJ, Choi EJ, et al. Cloning and cell type‐specific regulation of the human tyrosine hydroxylase gene promoter. Biochem Biophys Res Commun 2003 ; 312: 1123–1131.
27. 27 Zhang T, Jia N, Fei E, et al. Nurr1 is phosphorylated by ERK2 in vitro and its phosphorylation upregulates tyrosine hydroxylase expression in SH‐SY5Y cells. Neurosci Lett 2007 ; 423: 118–122.
28. 28 Corbitt J, Vivekananda J, Wang SS, Strong R. Transcriptional and posttranscriptional control of tyrosine hydroxylase gene expression during persistent stimulation of pituitary adenylate cyclase‐activating polypeptide receptors on PC12 cells: regulation by protein kinase A‐dependent and protein kinase A‐independent pathways. J Neurochem 1998 ; 71: 478–486.
29. 29 West GJ, Uki J, Herschman HR, Seeger RC. Adrenergic, cholinergic, and inactive human neuroblastoma cell lines with the action‐potential Na + ionophore. Cancer Res 1977 ; 37: 1372–1376.
30. 30 Bilang‐Bleuel A, Revah F, Colin P, et al. Intrastriatal injection of an adenoviral vector expressing glial‐cell‐line‐derived neurotrophic factor prevents dopaminergic neuron degeneration and behavioral impairment in a rat model of Parkinson disease. Proc Natl Acad Sci USA 1997 ; 94: 8818–8823.
31. 31 Stanic D, Finkelstein DI, Bourke DW, Drago J, Horne MK. Timecourse of striatal re‐innervation following lesions of dopaminergic SNpc neurons of the rat. Eur J Neurosci 2003 ; 18: 1175–1188.
32. 32 Anastasia A, de Erausquin GA, Wojnacki J, Masco DH. Protection of dopaminergic neurons by electroconvulsive shock in an animal model of Parkinson's disease. J Neurochem 2007 ; 103: 1542–1552.
33. 33 Chu C, Zhang Y, Boado RJ, Pardridge WM. Decline in exogenous gene expression in primate brain following intravenous administration is due to plasmid degradation. Pharm Res 2006 ; 23: 1586–1590.
34. 34 Boado RJ, Zhang YF, Zhang Y, Pardridge WM. Humanization of anti‐human insulin receptor antibody for drug targeting across the human blood‐brain barrier. Biotechnol Bioeng 2007 ; 96: 381–391.